Laurus Labs, a leading pharmaceutical company, reported a consolidated net profit of ₹279 crore for the quarter ending March 2026, a 19% increase compared to ₹234 crore in the same quarter last year. The revenue from operations rose 5% to ₹1,812 crore, up from ₹1,720 crore in Q4 FY25. This growth is attributed to strong performance in both the Contract Development and Manufacturing Organization (CDMO) and Affordable Medicine divisions. The profit after tax (PAT) also showed an 11% increase quarter-on-quarter from ₹252 crore in Q3 FY26. The company's EBITDA for the quarter was ₹523 crore, a 10% rise from ₹477 crore in Q4 FY25. For the full fiscal year, net profit surged to ₹889 crore, marking a 148% increase from ₹358 crore in FY25, with total revenues reaching ₹6,813 crore, a 23% growth year-on-year. The board approved a second interim dividend of ₹1.20, with a record date set for May 8, 2026, and payment scheduled for on or after May 20, 2026. The company's operating cash flow improved due to higher EBITDA and better net working capital management.